RE:RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to PelaMutations in both KRAS and TP53 genes are found in around 80% and 70% of all human pancreatic cancers respectively.
Mutant KRAS, found in 95% of pancreatic cancers, leads to an activated protein that aberrantly triggers many downstream signaling pathways. Mutant TP53 results in the loss of the proteins’ tumor suppressor function, leaving the mutant protein capable of fueling additional oncogenic processes, such as metastasis.
ONCYs pelareorep demonstrates to be effective in the knockdown of both KRAS (G12D/G12V KRAS mutations) and p53 gene activity, and ultimately effective in the treatment of pancreatic and GI cancers